Loading
A phase 2 trial of Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study is a phase 2 interventional study registered as NCT04589845 by Hoffmann-La Roche, with 920 participants enrolled, started 2021-01-18 and due to reach its primary completion in 2032-09-25. Interventions recorded: Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Trastuzumab emtansine, Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipatasertib, Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipatasertib, Inavolisib, Flatiron Health (Roche) and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Trastuzumab emtansine, Atezolizumab and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/